Mikah assumed the research and development role during a period of economic uncertainty when Lannett withdrew from its distribution contract fort Adderall. Likewise, as he well knows, the Adderall purchase was deferred until the company could assess the success of self distribution as discussed on the conference call. Mikah's share is currently 25% of the Adderall profits.
Mikah is what it has always been. A huge super dense sponge taking monies that should be ELTP's. It is an artificial company to enrich NasRat. Nothing has changed.